middle.news
Lumos Diagnostics Boosts FY26 Revenue 6% on FebriDx Growth and CLIA Milestones
9:55am on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Lumos Diagnostics Boosts FY26 Revenue 6% on FebriDx Growth and CLIA Milestones
9:55am on Monday 27th of July, 2026 AEST
Key Points
FY26 revenue rose 6% to US$13.2 million
FebriDx sales surged 875% after CLIA waiver
170+ U.S. healthcare sites now using FebriDx
BARDA paediatric study milestone payment of US$0.7 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics (ASX:LDX)
OPEN ARTICLE